Compare CNET & PCSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNET | PCSA |
|---|---|---|
| Founded | 2003 | 2011 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5M | 8.2M |
| IPO Year | 2009 | 2012 |
| Metric | CNET | PCSA |
|---|---|---|
| Price | $0.68 | $2.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | 6.0K | ★ 53.8K |
| Earning Date | 05-19-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $46,633,000.00 | $5,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 34.20 | N/A |
| 52 Week Low | $0.57 | $0.11 |
| 52 Week High | $2.78 | $8.88 |
| Indicator | CNET | PCSA |
|---|---|---|
| Relative Strength Index (RSI) | 45.47 | 47.42 |
| Support Level | $0.62 | $1.96 |
| Resistance Level | $0.84 | $3.30 |
| Average True Range (ATR) | 0.08 | 0.28 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 23.40 | 23.53 |
ZW Data Action Technologies Inc provides one-stop services for clients on its Omni-channel advertising, precision marketing, influencer marketing and data analysis management system. It also develops block-chain enabled web/mobile applications and provides Software-as-a-Service services for clients. In addition, it provides intellectual property licensing services. The company derives revenue from distributing the right to use search engine marketing service it purchased from key search engines to increase the sales conversion rate for clients business promotion on both mobile and computer searches; providing internet advertising and related marketing services for clients businesses; providing intellectual property licensing services; and providing Blockchain-based SaaS Services.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The four NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS11T, also referred to as NGC-Iri, is an analog of SN38, and PCS11T, PCS12852, and PCS499.